Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B3 | P37058 | 1/20 | 0.48 |
| ▸ | AVPR2 | P30518 | 15/20 | 0.45 |
| ▸ | AVPR1A | P37288 | 7/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4137666 | 0.88 | AVPR2 (0.61) | HSD17B3AVPR2AVPR1APOLBALDH1A1 | |
| SCHEMBL4146709 | 0.87 | AVPR2 (0.49) | AVPR2AVPR1A | |
| SCHEMBL4145689 | 0.85 | TSHR (0.48) | HSD17B3AVPR2AVPR1AALDH1A1 | |
| SCHEMBL4140577 | 0.83 | AVPR2 (0.48) | AVPR2AVPR1APOLBALDH1A1GAA | |
| SCHEMBL4138774 | 0.83 | AVPR2 (0.61) | AVPR2AVPR1A | |
| SCHEMBL4150438 | 0.75 | AVPR2 (0.66) | AVPR2AVPR1A | |
| SCHEMBL7079353 | 0.75 | AVPR2 (0.44) | HSD17B3AVPR2AVPR1APOLBALDH1A1 | |
| SCHEMBL4150860 | 0.74 | AVPR2 (0.61) | HSD17B3AVPR2AVPR1AALDH1A1 | |
| SCHEMBL13602473 | 0.73 | DHODH (0.53) | HSD17B3PDK2 | |
| SCHEMBL4154260 | 0.71 | AVPR2 (0.46) | HSD17B3AVPR2AVPR1APOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227565-A1 | Biphenyl Vasopressin Agonists | WYETH (US) | 2009-09-10 | — | — | US | claimed |
| US-7223752-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2007-05-29 | — | — | US | claimed |
| EP-1381370-B1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH CORP (US) | 2007-03-07 | — | — | EP | claimed |
| US-20050075328-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2005-04-07 | — | — | US | claimed |
| EP-1381370-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | Wyeth (US) | 2004-01-21 | — | — | EP | claimed |
| US-20030018024-A1 | Biphenyl vasopressin agonists | WYETH | 2003-01-23 | — | — | US | claimed |
| WO-2002083145-A1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH (US) | 2002-10-24 | — | — | WO | claimed |
| US-20090227565-A1 | Biphenyl Vasopressin Agonists | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7465722-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2008-12-16 | — | — | US | disclosed |
| US-7223752-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2007-05-29 | — | — | US | disclosed |
| EP-1381370-B1 | N-BIPHENYLCARBONYL- AND N-PHENYLPYRIDYLCARBONYL SUBSTITUTED BI- AND TRICYCLIC AZEPINES AND DIAZEPINES AS VASOPRESSING AGONISTS | WYETH CORP (US) | 2007-03-07 | — | — | EP | disclosed |
| US-20060276456-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2006-12-07 | — | — | US | disclosed |
| US-6903091-B2 | Biphenyl vasopressin agonists | WYETH (US) | 2005-06-07 | — | — | US | disclosed |
| US-20050075328-A1 | Biphenyl vasopressin agonists | WYETH (US) | 2005-04-07 | — | — | US | disclosed |
| US-20030018024-A1 | Biphenyl vasopressin agonists | WYETH | 2003-01-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090227565-A1 | Biphenyl Vasopressin Agonists | AVPR2, AVPR1B, SSTR3 | HSD17B3 225/4885AVPR2 1/4885AVPR1A 4/4885 |
| US-20060276456-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, SSTR3 | HSD17B3 225/4885AVPR2 1/4885AVPR1A 4/4885 |
| US-20030018024-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, AVPR1A | HSD17B3 356/4885AVPR2 1/4885AVPR1A 3/4885 |
| US-20050075328-A1 | Biphenyl vasopressin agonists | AVPR2, AVPR1B, SSTR3 | HSD17B3 225/4885AVPR2 1/4885AVPR1A 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.